Pharmafile Logo

Research Partnership ranks 13th in the top 20 fastest-growing agencies in the UK

February 4, 2019 | Pharma, healthcare, market research 

The UK’s best performing market research agencies were revealed earlier this month with the publication of Research Live’s Industry Report for 2019, which includes the latest Market Research Society (MRS) League Tables. Based on 2017 financial data that was compiled and analysed in November 2018, the MRS league tables identify and rank the best-performing research agencies and businesses according to their UK-based turnover and by their year-on-year growth.

With a growth rate of 21.87%, Research Partnership has been ranked 13th in the top 20 fastest-growing individual agencies. In addition, with over £27.5 million in sales, the company ranked 25th in the top 50 consolidated businesses, which draws agencies together under ownership groups, and 27th in the top 100 individual agencies, both of which are ranked by annual turnover.

Founding Director Mark Jeffery was interviewed for the report’s ‘Perspective from the Fastest Growers’ to find out how Research Partnership is achieving growth in an uncertain climate. Mark commented, “We are delighted to see Research Partnership placed so well in the league tables again this year. Our senior level and business development teams work hard to secure new clients, and our research teams ensure that we receive repeat business by delivering the very best service. We celebrated our 20th anniversary last year and have enjoyed consistent growth every year since we started. As a result we are now the largest independent healthcare market research agency in the world, working with all the major global pharma organisations.”

In the past year Research Partnership’s has also expanded into the medical technology space, built up the company’s market access capabilities, opened three new offices across the US and Europe, and grown the workforce by 15%.

Read the full report here »

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 – Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.